{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-034348","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.679619+00:00","generated_at":"2026-06-19T16:26:53.478328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled","bullets":["Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.","Cash and cash equivalents $10.5M at Dec 31, 2022, up from $4.1M at June 30, 2022.","First patient enrolled in OPMD natural history study in Jan 2023; part of BB-301 program.","Expects IND/CTA clearance in Q2 2023; first BB-301 dosing anticipated in Q3 2023.","R&D expenses $3.8M, up $0.7M YoY due to toxicology and manufacturing projects."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-034348","json":"https://secwatch.observer/filing/0001193125-23-034348.json","markdown":"https://secwatch.observer/filing/0001193125-23-034348.md","text":"https://secwatch.observer/filing/0001193125-23-034348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/0001193125-23-034348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/d375301d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:26:53.478328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24b0b333aff31005df2093590ff343831e4166a9","claim":"Benitec Biopharma Inc. reported financial results for Second Fiscal Quarter ended December 31, 2022.","evidence_excerpt":"On February 13, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/0001193125-23-034348-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Second Fiscal Quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}